Comparison of the Effectiveness and Safety of Allopurinol and Febuxostat Use in CKD Patients with Hyperuricemia: A Systematic Review
DOI:
https://doi.org/10.35451/jfm.v9i1.3890Keywords:
Chronic Kidney Disease, Hyperuricemia, Febuxostat, Allopurinol, Renal Function, Systematic ReviewAbstract
Background: Hyperuricemia is common in patients with Chronic Kidney Disease (CKD) and may accelerate renal function decline and increase cardiovascular risk. Allopurinol and febuxostat are xanthine oxidase inhibitors, but their comparative efficacy and safety remain inconsistent.Objective: To compare the effectiveness and safety of allopurinol and febuxostat in patients with CKD and hyperuricemia. Methods: This systematic review was conducted according to the PRISMA 2020 guidelines and prospectively registered. A literature search was performed in the PubMed, ScienceDirect, and Google Scholar databases for articles published between 2021 and 2025. The quality assessment (risk of bias) was conducted using the JBI Critical Appraisal Tools and the Newcastle-Ottawa Scale (NOS). The inclusion criteria comprised comparative clinical studies (RCTs and cohort studies) comparing allopurinol and febuxostat in patients with CKD stages 3–5. Results: Of the 50 articles identified, following rigorous PRISMA screening, 8 original articles met the inclusion criteria and were analyzed, excluding non-comparative and animal studies. The majority of studies showed that febuxostat resulted in a greater reduction in serum uric acid levels, as well as improvements in estimated glomerular filtration rate (eGFR) and serum creatinine parameters. In contrast, large-scale cohort studies reported that allopurinol was more consistent in slowing CKD progression and demonstrated more favorable cardiovascular outcomes in certain populations. The risk-of-bias assessment confirmed that the methodological quality of the included studies ranged from moderate to high. Conclusion: Febuxostat appears to be superior in reducing serum uric acid levels, whereas allopurinol demonstrates greater consistency in renal protection and cardiovascular outcomes in long-term cohort studies. The choice of therapy should be individualized based on CKD stage, cardiovascular risk profile, comorbidities, and safety considerations.
Downloads
References
1. Peng, Y., et al. (2020). Comparing the Efficacy and Safety of Febuxostat and Allopurinol in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Clinical Therapeutics, 42(6), 1105–1117.
2. Sylvertooth, D., et al. (2026). Gout Prevalence and Management Strategies Among Patients with Moderate to Advanced Chronic Kidney Disease. Journal of Nephrology Nursing, 38(1), 15–22.
3. Alatas, H. (2021). Penatalaksanaan Hiperurisemia pada Penyakit Ginjal Kronik. Jurnal Penyakit Dalam Indonesia, 8(3), 142–150.
4. Sun, M., et al. (2022). Allopurinol Lowers Serum Urate but Does Not Reduce Oxidative Stress in CKD. Free Radical Biology and Medicine, 182, 88–95.
5. Vargas-Santos, A. B., Peloquin, C. E., & Neogi, T. (2025). Effect of Allopurinol Use on Kidney Function Among Patients with Gout and Chronic Kidney Disease. Arthritis & Rheumatology, 77(1), 65–73.
6. Liu, C., et al. (2021). Effectiveness of Drug Treatments for Lowering Uric Acid on Renal Function in Patients With Chronic Kidney Disease and Hyperuricemia: A Network Meta-Analysis. Frontiers in Pharmacology, 12, 654321.
7. Alobaidi, S., et al. (2021). The Pattern of Allopurinol Prescription Among Chronic Kidney Disease Patients in a Tertiary Care Centre. Saudi Journal of Kidney Diseases and Transplantation, 32(4), 1012–1020.
8. Hsu, C. C., et al. (2020). Febuxostat versus Allopurinol and Risk of End-Stage Renal Disease in Patients with CKD. American Journal of Medicine, 133(8), 950–958.
9. Otani, M., et al. (2024). Association Between Febuxostat Use and the Incidence of Cardiovascular Events, Mortality, and Kidney Events in Patients With CKD Compared to Allopurinol. Renal Failure, 46(1), 230124.
10. Liao, Y., et al. (2022). Comparison of Febuxostat and Allopurinol in CKD Stage 3–5 Patients with Hyperuricemia: A Randomized Controlled Trial. Clinical Nephrology, 98(4), 185–193.
11. Matta, S., et al. (2023). Comparison Between Renoprotective Effects of Febuxostat and Allopurinol in Chronic Kidney Disease Patients with Hyperuricemia. Egyptian Journal of Internal Medicine, 35(1), Article 22.
12. Park, S., et al. (2022). Superior Effect of Allopurinol Compared to Febuxostat on the Retardation of Chronic Kidney Disease Progression. Kidney Research and Clinical Practice, 41(3), 320–329.
13. Ishii, H., et al. (2024). Allopurinol, Febuxostat, and Cardiovascular Outcomes in Hemodialysis Patients. Nephrology Dialysis Transplantation, 39(3), 481–489.
14. Huang, H. H., et al. (2024). Comparative Cardiovascular Risks of Febuxostat and Allopurinol in Patients with Diabetes Mellitus and Chronic Kidney Disease. Cardiovascular Diabetology, 23(1), Article 112.
15. Ahmad, M., et al. (2022). Efficacy of Febuxostat with Allopurinol in Chronic Kidney Disease Patients: A Comparative Study. Journal of Renal Therapeutics, 11(2), 45–50.
16. Nagaraju, S. P., et al. (2023). Effect of Febuxostat versus Allopurinol on the Glomerular Filtration Rate and Hyperuricemia in Patients with Chronic Kidney Disease. Indian Journal of Nephrology, 33(2), 105–111.
17. Inoue, R., et al. (2025). Allopurinol Versus Febuxostat Use and the Risk of Cardiovascular Disease in People With Chronic Kidney Disease: A New-User Active Comparator Cohort Study. Journal of the American Heart Association, 14(2), e031204.
18. Ashraf U, Khan AA, Javed M, Umar RM, Sarwar S, Ashraf HH. Efficacy of febuxostat for the prevention of progression of chronic kidney disease in hyperuricemia patients. Pak J Med Health Sci. 2022;16(8):122. doi:10.53350/pjmhs22168122.
19. Shuvo AUH, Alimullah M, Jahan I, Mitu KF, Rahman MJ, Akramuddaula K, et al. Evaluation of xanthine oxidase inhibitors febuxostat and allopurinol on kidney dysfunction and histological damage in two-kidney, one-clip (2K1C) rats. Scientifica. 2025;2025:7932075. doi:10.1155/sci5/7932075.
20. Latjandu, N. C., & Sa’adah, I. (2026). Unidentified Drug-Related Problems (DRPs) Associated with Self-Medication in Patients with Type 2 Diabetes Mellitus and CKD. JURNAL FARMASIMED (JFM), 8(2), 641-650.
21. Depari, E., & Malisie, R. F. (2025). A Review: Propolis As An Antiinflammatory Adjunct Therapy in Chronic Kidney Disease. JURNAL FARMASIMED (JFM), 7(2), 293-301.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Fiolita Etsa Aurora, Ida Paulina Sormin
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright in each article is the property of the Author.
